Nab-paclitaxel, an albumin-bound nanoparticle formulation of paclitaxel, has emerged as a critical component in the treatment of triple-negative breast cancer (TNBC), particularly in combination with immune checkpoint inhibitors such as atezolizumab. This evidence concerns the gene ALB and triple-negative breast carcinoma.